NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 314.75 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.17
▲ +0.05 (2.36%)
1 month | 3 months | 12 months
Get New Pieris Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PIRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PIRS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.00
▲ +314.75% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Pieris Pharmaceuticals in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 314.75% upside from the last price of $2.17.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Pieris Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2021HC WainwrightReiterated RatingBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
8/10/2020HC WainwrightReiterated RatingBuyLow
i
Rating by J. Pantginis at HC Wainwright
8/9/2020William BlairReiterated RatingOutperformHigh
i
7/23/2020HC WainwrightReiterated RatingBuyMedium
i
3/13/2020Robert W. BairdUpgradeNeutral ➝ Outperform$5.00High
i
1/27/2020HC WainwrightBoost Price TargetBuy$7.00 ➝ $9.00Low
i
Rating by Joseph Pantginis at HC Wainwright
11/11/2019William BlairReiterated RatingBuyHigh
i
Rating by Matt Phipps at William Blair
11/11/2019HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Joseph Pantginis at HC Wainwright
9/27/2019William BlairReiterated RatingBuyHigh
i
9/27/2019HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/16/2019William BlairReiterated RatingBuyHigh
i
8/1/2019HC WainwrightReiterated RatingBuy$7.00Low
i
Rating by Joseph Pantginis at HC Wainwright
7/30/2019Robert W. BairdDowngradeOutperform ➝ Neutral$5.00High
i
6/17/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/23/2019HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/13/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$5.00High
i
5/13/2019CowenReiterated RatingBuyHigh
i
5/10/2019HC WainwrightReiterated RatingBuy$5.00 ➝ $7.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/19/2019HC WainwrightReiterated RatingBuy$5.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
11/11/2018CowenReiterated RatingBuyHigh
i
11/7/2018HC WainwrightSet Price TargetBuy$5.00Low
i
Rating by Joseph Pantginis at HC Wainwright
9/4/2018HC WainwrightSet Price TargetBuy$12.00Low
i
Rating by Joseph Pantginis at HC Wainwright
8/9/2018HC WainwrightSet Price TargetBuy$12.00High
i
Rating by Joseph Pantginis at HC Wainwright
6/7/2018HC WainwrightSet Price TargetBuy$12.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
5/10/2018HC WainwrightSet Price TargetBuy$12.00Low
i
Rating by Joseph Pantginis at HC Wainwright
5/4/2018CowenInitiated CoverageOutperformHigh
i
3/19/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$13.00High
i
Rating by Umer Raffat at Evercore ISI
3/19/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$12.00High
i
3/9/2018HC WainwrightReiterated RatingBuy$12.00High
i
Rating by Joseph Pantginis at HC Wainwright
2/9/2018HC WainwrightSet Price TargetBuy$12.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/17/2018William BlairInitiated CoverageOutperformHigh
i
Rating by M. Phipps at William Blair
1/16/2018HC WainwrightBoost Price TargetBuy$9.00 ➝ $12.00High
i
Rating by Joseph Pantginis at HC Wainwright
12/20/2017HC WainwrightSet Price TargetBuy$9.00Low
i
Rating by Joseph Pantginis at HC Wainwright
11/10/2017HC WainwrightReiterated RatingBuy$9.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/18/2017HC WainwrightSet Price TargetBuy$9.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/2/2017HC WainwrightSet Price TargetBuy$9.00Medium
i
Rating by Joseph Pantginis at HC Wainwright
8/11/2017HC WainwrightSet Price TargetBuy$9.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/30/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$9.00High
i
4/12/2017OppenheimerSet Price TargetBuy$9.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
9/28/2016OppenheimerReiterated RatingOutperform$10.00N/A
i
9/28/2016Roth CapitalReiterated RatingBuy$6.00N/A
i
8/5/2016Roth CapitalReiterated RatingBuy$6.00N/A
i
Rating by Elemer Piros at Roth Capital
(Data available from 4/19/2016 forward)
Pieris Pharmaceuticals logo
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $2.17
$2.10
$2.22

50 Day Range

MA: $2.61
$2.09
$2.87

52 Week Range

Now: $2.17
$1.95
$3.64

Volume

28,790 shs

Average Volume

522,610 shs

Market Capitalization

$129.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Pieris Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Pieris Pharmaceuticals in the last year: HC Wainwright, William Blair, and Zacks Investment Research.
View the latest analyst ratings for PIRS.

What is the current price target for Pieris Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Pieris Pharmaceuticals in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 324.5%. HC Wainwright has the highest price target set, predicting PIRS will reach $9.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.00 for Pieris Pharmaceuticals in the next year.
View the latest price targets for PIRS.

What is the current consensus analyst rating for Pieris Pharmaceuticals?

Pieris Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PIRS will outperform the market and that investors should add to their positions of Pieris Pharmaceuticals.
View the latest ratings for PIRS.

What other companies compete with Pieris Pharmaceuticals?

How do I contact Pieris Pharmaceuticals' investor relations team?

Pieris Pharmaceuticals' physical mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company's listed phone number is 857-246-8998 and its investor relations email address is [email protected] The official website for Pieris Pharmaceuticals is www.pieris.com.